Related Experiment Video
Updated: Jun 20, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Left ventricular assist device placement in a patient with end-stage heart failure and human immunodeficiency virus
David S Fieno1, Lawrence S Czer, Ernst R Schwarz
1Cedars-Sinai Medical Center, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Abstract:
Left ventricular assist device (LVAD) insertion has been used more frequently within the recent years either as a bridge to transplant or as destination therapy in patients with advanced heart failure who fail medical therapy. We present a report of a 60-year-old male patient with end-stage heart failure and cardiomyopathy with a history of human immunodeficiency virus (HIV) infection who underwent LVAD placement as destination therapy. To our knowledge, LVAD placement in this fashion has not been reported previously. Following LVAD implantation, the patient recovered during the course of five weeks and was discharged home from the hospital in good condition. The patient was alive and free of any activity limitations sixteen months postoperatively. We conclude that LVAD placement for end-stage heart failure may be a feasible option as destination therapy in patients with HIV.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure V: Medical Management
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Heart Failure IV: Classification and Diagnostic Evaluation
